BNP Paribas Financial Markets Purchases 3,171 Shares of Xencor, Inc. (NASDAQ:XNCR)

BNP Paribas Financial Markets boosted its position in Xencor, Inc. (NASDAQ:XNCR) by 23.7% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 16,528 shares of the biopharmaceutical company’s stock after acquiring an additional 3,171 shares during the quarter. BNP Paribas Financial Markets’ holdings in Xencor were worth $380,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the company. Vanguard Group Inc. boosted its holdings in shares of Xencor by 5.5% in the 4th quarter. Vanguard Group Inc. now owns 8,017,366 shares of the biopharmaceutical company’s stock valued at $184,239,000 after purchasing an additional 418,040 shares in the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of Xencor by 2.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,036,412 shares of the biopharmaceutical company’s stock worth $92,758,000 after buying an additional 107,350 shares in the last quarter. TCG Crossover Management LLC lifted its position in shares of Xencor by 1.0% during the 4th quarter. TCG Crossover Management LLC now owns 2,452,138 shares of the biopharmaceutical company’s stock worth $56,350,000 after buying an additional 25,000 shares during the last quarter. Geode Capital Management LLC boosted its stake in Xencor by 12.3% in the fourth quarter. Geode Capital Management LLC now owns 1,634,876 shares of the biopharmaceutical company’s stock valued at $37,578,000 after buying an additional 179,526 shares in the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in Xencor by 7.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,501,532 shares of the biopharmaceutical company’s stock valued at $34,509,000 after buying an additional 102,297 shares in the last quarter.

Insiders Place Their Bets

In other news, EVP Nancy Valente sold 4,616 shares of the stock in a transaction dated Friday, May 2nd. The stock was sold at an average price of $11.03, for a total value of $50,914.48. Following the completion of the sale, the executive vice president now owns 49,169 shares of the company’s stock, valued at approximately $542,334.07. This represents a 8.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 4.76% of the company’s stock.

Analyst Ratings Changes

XNCR has been the subject of several research analyst reports. Wall Street Zen downgraded Xencor from a “hold” rating to a “sell” rating in a research note on Friday, March 14th. William Blair started coverage on shares of Xencor in a report on Monday, April 21st. They set an “outperform” rating on the stock. Barclays lowered their price objective on shares of Xencor from $22.00 to $6.00 and set an “underweight” rating for the company in a research report on Thursday, May 8th. Wedbush restated an “outperform” rating and issued a $31.00 target price on shares of Xencor in a research report on Wednesday, April 30th. Finally, Wells Fargo & Company decreased their target price on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research note on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Xencor has an average rating of “Moderate Buy” and an average price target of $29.50.

Xencor Stock Down 1.6%

NASDAQ:XNCR opened at $7.57 on Monday. Xencor, Inc. has a one year low of $7.16 and a one year high of $27.24. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The company has a market cap of $538.76 million, a PE ratio of -2.37 and a beta of 0.99. The firm’s 50 day simple moving average is $9.67 and its 200 day simple moving average is $16.66.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.06). Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. The business had revenue of $32.73 million for the quarter, compared to the consensus estimate of $23.44 million. During the same period in the previous year, the business posted ($1.11) EPS. Xencor’s revenue was up 104.6% on a year-over-year basis. On average, research analysts anticipate that Xencor, Inc. will post -3.68 earnings per share for the current year.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.